AAO 2024: Epimacular membranes and metamorphopsia

News
Video

At this year's American Academy of Ophthalmology (AAO) meeting, Jonathan Brugger, MD, spoke about the changing approach to epimacular membranes and the use of brilliant blue in the procedure.

At this year's American Academy of Ophthalmology (AAO) meeting, Jonathan Brugger, MD, spoke about the changing approach to epimacular membranes and the use of brilliant blue in the procedure.

Editor's note: This transcript has been lightly edited for clarity.

Jonathan Brugger, MD: I'm Dr Jonathan Brugger. I'm a vitreoretinal surgeon with Carolina Eye Care in Charleston, South Carolina. And I wanted to shed some light on epimacular membranes. A lot of the teaching that we have been taught in generations was that "we don't want to touch epimacular membranes until they are visually significant."

However, with safer procedures, better instruments, and now non-toxic, brilliant blue, we should be having earlier intervention on epimacular membranes, to the point that surgeons now are approaching patients that are symptomatic with metamorphopsia to peel even [a] 20/20 vision eye. That's simply because individuals can see that it's the letter T, whether it's perfectly straight or if it's slightly twisted, but the patients now that we are peeling early, have quicker resolution of their metamorphopsia and report that the vision is actually better, that the T is straight, if you will, and we have not caused any harm to the retina. With the non-toxic brilliant blue, we feel confident that we're getting all of the membrane because we're able to re-stain multiple times.

The adage of "waiting until the membrane gets bad enough," you will be sitting there for a lifetime, because we do know that a majority of these membranes will form and then they do not progress. So you will be watching these patients for years and years and years that are symptomatic but not getting better. And now, I think the time has come that we should start looking at this again for early intervention of peeling symptomatic epimacular membranes.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.